Jazz director sells 6,000 shares under 10b5-1 plan

Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026 at an average price of $240.47 per share.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc director Bruce C. Cozadd reported an open-market sale of 6,000 Ordinary Shares of JAZZ on July 1, 2026 at an average price of $240.47 per share. The filing shows that Cozadd continues to directly hold 366,682 Ordinary Shares after this transaction.

According to the disclosure, the trade was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, meaning the timing was set in advance and was not a discretionary decision by the reporting person.

Insider Trade Summary 10b5-1

Net Seller: 6,000 shares

Net Sell 1 txn

Insider COZADD BRUCE C

Role Director

Sold 6,000 shs ($1.44M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	6,000	$240.47	$1.44M

Holdings After Transaction: Ordinary Shares — 366,682 shares (Direct)

Footnotes (1)

1. F1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

Key Figures

Shares sold: 6,000 shares Sale price: $240.47 per share Shares held after transaction: 366,682 shares +3 more

6 metrics

Shares sold 6,000 shares Ordinary Shares sold on July 1, 2026

Sale price $240.47 per share Average price for the 6,000 shares sold

Shares held after transaction 366,682 shares Direct ownership after the reported sale

Transaction code S (sale) Open-market or private sale of non-derivative securities

Trading plan adoption date November 26, 2025 Date Rule 10b5-1 plan was adopted

Transaction date July 1, 2026 Date of the reported share sale

Key Terms

Rule 10b5-1, open-market sale, Ordinary Shares, Form 4, +1 more

5 terms

Rule 10b5-1 regulatory

"plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

""security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

direct ownership financial

""ownership_type": "direct""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Jazz Pharmaceuticals (JAZZ) director Bruce C. Cozadd report in this Form 4?

Bruce C. Cozadd reported selling 6,000 Jazz Pharmaceuticals Ordinary Shares in an open-market transaction. The sale occurred at an average price of $240.47 per share, and he retained 366,682 shares directly after the trade.

At what price did Bruce C. Cozadd sell Jazz Pharmaceuticals (JAZZ) shares?

He sold the 6,000 Ordinary Shares at an average price of $240.47 per share. This price reflects the transaction reported in the Form 4 and is based on trades executed on July 1, 2026.

How many Jazz Pharmaceuticals (JAZZ) shares does Bruce C. Cozadd hold after this transaction?

After the reported sale, Bruce C. Cozadd directly holds 366,682 Ordinary Shares of Jazz Pharmaceuticals. This post-transaction balance is disclosed in the Form 4 as his direct ownership position.

Was Bruce C. Cozadd’s Jazz Pharmaceuticals (JAZZ) share sale discretionary?

No. The filing states the sale was made under a Rule 10b5-1 trading plan adopted on November 26, 2025. The transaction occurred automatically and is described as not representing a discretionary decision by Cozadd.

What is the significance of the Rule 10b5-1 plan mentioned in the Jazz (JAZZ) Form 4?

The Rule 10b5-1 plan means trades were pre-scheduled according to a plan adopted on November 26, 2025. This structure allows insiders to sell shares automatically, helping separate trading activity from day-to-day discretionary decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 06:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COZADD BRUCE C

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/01/2026		S(1)		6,000	D	$240.47	366,682	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.

	By: /s/Paz Dizon, as attorney in fact For: Bruce C Cozadd	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)